Syndax Pharmaceuticals, Inc.
SNDX
Rank in Stocks
#9379
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Share Price
$9.55
Last synced: 2026-11-09
Market Cap
$859.77M
Change (1 day)
0.10%
Change (1 year)
-43.12%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Syndax Pharmaceuticals, Inc. (SNDX)
Category
Healthcare
Operating Margin for Syndax Pharmaceuticals, Inc. (SNDX)
Operating Margin as of November 2026 TTM: -77.05%
According to Syndax Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -77.05%. At the end of 2025 the company had an operating margin of -158.45%.
Operating Margin history for Syndax Pharmaceuticals, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -77.05% | -51.37% |
| 2025 | -158.45% | -88.95% |
| 2024 | -1,434.43% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | 18.77% | -100.40% |
| 2020 | -4,708.17% | 24.13% |
| 2019 | -3,792.95% | -24.17% |
| 2018 | -5,001.71% | 70.18% |
| 2017 | -2,938.99% | -18.07% |
| 2016 | -3,587.38% | 9.65% |
| 2015 | -3,271.61% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.50% |
US
|
|
| -149.01% | -98.07% |
US
|
|
| 25.57% | -100.33% |
AU
|
|
| 31.23% | -100.41% |
BE
|
|
| 29.35% | -100.38% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Syndax Pharmaceuticals, Inc.'s operating margin
What is Syndax Pharmaceuticals, Inc.'s operating margin?
Syndax Pharmaceuticals, Inc.'s operating margin is -77.05%, as of Nov 2026.
What was Syndax Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Syndax Pharmaceuticals, Inc.'s operating margin was -158.45%, compared with -1,434.43% in 2024.
How has Syndax Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Syndax Pharmaceuticals, Inc.'s operating margin was highest in 2021 (18.77%) and lowest in 2020 (-4,708.17%).
How does Syndax Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Syndax Pharmaceuticals, Inc.'s operating margin (-77.05%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.